{"id":12505,"date":"2026-03-04T08:00:28","date_gmt":"2026-03-04T08:00:28","guid":{"rendered":"https:\/\/magazines.uthscsa.edu\/mission\/?p=12505"},"modified":"2026-03-10T10:34:18","modified_gmt":"2026-03-10T10:34:18","slug":"personal-cancer-risk-guides-researchers-focus","status":"publish","type":"post","link":"https:\/\/magazines.uthscsa.edu\/mission\/personal-cancer-risk-guides-researchers-focus\/","title":{"rendered":"Personal cancer risk guides researcher\u2019s focus"},"content":{"rendered":"

The question that drives him: If metabolic health is central to cancer prevention, could GLP-1 therapies help prevent colorectal cancer?<\/em><\/span><\/h4>\n

 <\/p>\n

For Colton Jones, MD<\/a>, a first-year fellow in the Division of Hematology and Medical Oncology at the Joe R. and Teresa Lozano Long School of Medicine<\/a> at The University of Texas at San Antonio<\/a>, the question of cancer prevention has never been abstract.<\/p>\n

Jones has spent much of his adult life aware that colorectal cancer and metabolic disease run in his family.<\/p>\n

\u201cI\u2019ve known my entire adult life that I\u2019m at higher risk. It\u2019s affected how I think about food, health and long-term decisions,\u201d Jones said.<\/p>\n

That awareness shaped his relationship with health long before he entered medicine. It also shaped his future.<\/p>\n

With a strong genetic predisposition to colorectal cancer and a family history of Type 2 diabetes, which is a risk factor for colorectal cancer, Jones grew up understanding that prevention was essential. As he advanced through medical training and chose oncology as his specialty, he questioned whether there was a way to prevent cancer before it ever started.<\/p>\n

\"\"
Colton Jones, MD<\/figcaption><\/figure>\n

That question guided his research into colorectal cancer risk prevention<\/a>, which has now gained national attention.<\/p>\n

Jones recently presented his findings at the American Society of Clinical Oncology 2026 Gastrointestinal Cancers Symposium. Those findings suggest that glucagon-like peptide-1 (GLP-1) receptor agonist drugs may significantly reduce the risk of developing colorectal cancer.<\/p>\n

From personal risk to the national stage<\/strong><\/p>\n

GLP-1 receptor agonists have revolutionized metabolic healthcare, offering effective treatment for Type 2 diabetes and obesity. As their use expanded across the country, early studies began to show favorable side effects, including anticancer effects.<\/p>\n

This potential immediately caught Jones\u2019 eye.<\/p>\n

\u201cWhen I saw the early data suggesting these drugs might have anticancer properties, the first thing that came to mind was my family. I thought, what if this actually works?\u201d he said.<\/p>\n

Under the mentorship of Sukeshi Patel Arora, MD<\/a>, a gastrointestinal oncologist at the Mays Cancer Center at UT Health San Antonio<\/a> and professor in the Division of Hematology-Oncology in the Long School of Medicine, Jones studied whether GLP-1 receptor agonists were associated with reduced colorectal cancer incidence.<\/p>\n

\u201cThis study highlights how medications developed for metabolic disease may have far broader implications for oncology. Dr. Jones approached this question thoughtfully, and the findings open the door for future research that could reshape prevention and treatment strategies,\u201d said Arora.<\/p>\n

Using records from a large national medical database, Jones and his team analyzed outcomes from more than 280,000 patients. They compared people prescribed GLP-1 receptor agonists with a group taking aspirin. Aspirin has long been the standard medication studied for colorectal cancer prevention. To reduce bias, patients were balanced by demographic factors, underlying health conditions and cancer history.<\/p>\n

Jones remembers the pivotal moment the data began to take shape.<\/p>\n

\u201cWhen we first ran the analysis, we thought maybe weight loss would explain the effect, so we adjusted for [body mass index]. But the effect was still there. Then we adjusted for diabetes. We ran it again and again across subgroups, and every time we saw the same result,\u201d he said.<\/p>\n

Across multiple analyses, patients taking GLP-1 receptor agonists were 36% less likely to develop colorectal cancer than those taking aspirin. The benefit held, regardless of weight loss, BMI or diabetes status. The effect was strongest among people ages 18 to 44.<\/p>\n

For Jones, that finding was particularly important.<\/p>\n

Colorectal cancer is now the leading cause of cancer-related death among people under age 50 in the United States. Many scientists believe worsening metabolic health is playing a role.<\/p>\n

\u201cTo see the strongest benefit in younger people was incredible,\u201d Jones said.<\/p>\n

New angle on cancer prevention<\/strong><\/p>\n

GLP-1 receptor agonists may influence cancer risk through multiple pathways. The drugs reduce obesity-related inflammation, and they also improve insulin sensitivity, addressing some of cancer\u2019s known metabolic drivers.<\/p>\n

GLP-1 receptors are also expressed in the colon, where activation may improve the gut microbiome and reduce inflammatory signals linked to tumor development. Emerging scientific evidence suggests the drugs may inhibit the mechanistic target of rapamycin (mTOR) pathway, a key driver of cancer cell growth.<\/p>\n

\u201cThe drug\u2019s effect appears to be multifactorial with both indirect metabolic benefits and a direct anticancer effect,\u201d Jones said.<\/p>\n

Implications of these findings are significant. More than 20 million Americans are currently taking GLP-1 medications for diabetes or obesity. If future studies prove the association is causal, thousands of people may already be receiving cancer-prevention benefits.<\/p>\n

\u201cFor decades, we\u2019ve focused on treating cancer once it appears, and prevention has lagged behind. That\u2019s discouraging when rates of many kinds of cancer are on the rise,\u201d Jones said.<\/p>\n

His hope is that future longitudinal studies can follow participants over five to 10 years to determine whether GLP-1 therapies truly prevent colorectal cancer. If confirmed, the findings could influence national guidelines and regulatory recommendations.<\/p>\n

Future defined by prevention<\/strong><\/p>\n

Jones plans to pursue a career in academic and community medicine with a focus on gastrointestinal oncology and metabolic-driven cancer prevention. For him, metabolic health is central to cancer prevention.<\/p>\n

\u201cIn Western countries especially, the metabolic factors driving diabetes and obesity are also driving cancer risk. If we can control those factors, we could potentially lower cancer incidence globally,\u201d he said.<\/p>\n

At UT San Antonio, Jones says he found an environment where early-career physician-scientists are encouraged to ask ambitious questions and pursue data-driven answers.<\/p>\n

\u201cThis kind of research doesn\u2019t happen without mentorship and institutional support,\u201d Jones said.<\/p>\n

Still, the motivation behind his research remains personal.<\/p>\n

Every analysis, model or late-night data review carried a sense of urgency, not just for his patients, but also for his family, who first shaped his awareness of cancer risk.<\/p>\n

\u201cI thought about how can this benefit my patients, but also how can it benefit my family and the world? That\u2019s what drives me,\u201d Jones said.<\/p>\n

For him, cancer prevention research holds the key to a world where the growing threat of colorectal cancer will someday be a thing of the past.<\/p>\n

 <\/p>\n

Learn more about the colorectal cancer research<\/a>\u00a0of Colton Jones that is gaining national attention.<\/em><\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

First-year fellow Colton Jones, MD, is driven by the potential to prevent colorectal cancer \u2014 now the leading cause of cancer-related death among people under the age of 50 in the U.S. <\/p>\n","protected":false},"author":684,"featured_media":12523,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"ppma_author":[301],"class_list":["post-12505","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\nPersonal cancer risk guides researcher\u2019s focus - Mission Magazine<\/title>\n<meta name=\"description\" content=\"GLP-1 receptor agonists have revolutionized metabolic healthcare, offering effective treatment for Type 2 diabetes and obesity. As their use has expanded across the country, early studies by UT Health San Antonio researchers are beginning to show the potential anticancer effects of these therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/magazines.uthscsa.edu\/mission\/personal-cancer-risk-guides-researchers-focus\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Personal cancer risk guides researcher\u2019s focus - Mission Magazine\" \/>\n<meta property=\"og:description\" content=\"GLP-1 receptor agonists have revolutionized metabolic healthcare, offering effective treatment for Type 2 diabetes and obesity. As their use has expanded across the country, early studies by UT Health San Antonio researchers are beginning to show the potential anticancer effects of these therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/magazines.uthscsa.edu\/mission\/personal-cancer-risk-guides-researchers-focus\/\" \/>\n<meta property=\"og:site_name\" content=\"Mission Magazine\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-04T08:00:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-10T10:34:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/magazines.uthscsa.edu\/mission\/wp-content\/uploads\/sites\/20\/2026\/03\/ColtonJones_CAedit_v5-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2508\" \/>\n\t<meta property=\"og:image:height\" content=\"1173\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Claire Kowalick\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Claire Kowalick\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/personal-cancer-risk-guides-researchers-focus\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/personal-cancer-risk-guides-researchers-focus\\\/\"},\"author\":{\"name\":\"Claire Kowalick\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/#\\\/schema\\\/person\\\/2b00e59a35965b999b3404a426707181\"},\"headline\":\"Personal cancer risk guides researcher\u2019s focus\",\"datePublished\":\"2026-03-04T08:00:28+00:00\",\"dateModified\":\"2026-03-10T10:34:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/personal-cancer-risk-guides-researchers-focus\\\/\"},\"wordCount\":1031,\"publisher\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/personal-cancer-risk-guides-researchers-focus\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/wp-content\\\/uploads\\\/sites\\\/20\\\/2026\\\/03\\\/ColtonJones_CAedit_v5-1.jpg\",\"articleSection\":[\"Current\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/personal-cancer-risk-guides-researchers-focus\\\/\",\"url\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/personal-cancer-risk-guides-researchers-focus\\\/\",\"name\":\"Personal cancer risk guides researcher\u2019s focus - Mission Magazine\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/personal-cancer-risk-guides-researchers-focus\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/personal-cancer-risk-guides-researchers-focus\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/wp-content\\\/uploads\\\/sites\\\/20\\\/2026\\\/03\\\/ColtonJones_CAedit_v5-1.jpg\",\"datePublished\":\"2026-03-04T08:00:28+00:00\",\"dateModified\":\"2026-03-10T10:34:18+00:00\",\"description\":\"GLP-1 receptor agonists have revolutionized metabolic healthcare, offering effective treatment for Type 2 diabetes and obesity. As their use has expanded across the country, early studies by UT Health San Antonio researchers are beginning to show the potential anticancer effects of these therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/personal-cancer-risk-guides-researchers-focus\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/personal-cancer-risk-guides-researchers-focus\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/personal-cancer-risk-guides-researchers-focus\\\/#primaryimage\",\"url\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/wp-content\\\/uploads\\\/sites\\\/20\\\/2026\\\/03\\\/ColtonJones_CAedit_v5-1.jpg\",\"contentUrl\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/wp-content\\\/uploads\\\/sites\\\/20\\\/2026\\\/03\\\/ColtonJones_CAedit_v5-1.jpg\",\"width\":2508,\"height\":1173},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/personal-cancer-risk-guides-researchers-focus\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Personal cancer risk guides researcher\u2019s focus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/#website\",\"url\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/\",\"name\":\"Mission Magazine\",\"description\":\"The University of Texas Health Science Center at San Antonio Mission magazine\",\"publisher\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/#organization\",\"name\":\"Mission Magazine\",\"url\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/wp-content\\\/uploads\\\/sites\\\/20\\\/2024\\\/10\\\/UTHSA_logo_H_CMYK-350.jpg\",\"contentUrl\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/wp-content\\\/uploads\\\/sites\\\/20\\\/2024\\\/10\\\/UTHSA_logo_H_CMYK-350.jpg\",\"width\":350,\"height\":121,\"caption\":\"Mission Magazine\"},\"image\":{\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/#\\\/schema\\\/person\\\/2b00e59a35965b999b3404a426707181\",\"name\":\"Claire Kowalick\",\"url\":\"https:\\\/\\\/magazines.uthscsa.edu\\\/mission\\\/author\\\/claire-kowalick\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Personal cancer risk guides researcher\u2019s focus - Mission Magazine","description":"GLP-1 receptor agonists have revolutionized metabolic healthcare, offering effective treatment for Type 2 diabetes and obesity. As their use has expanded across the country, early studies by UT Health San Antonio researchers are beginning to show the potential anticancer effects of these therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/magazines.uthscsa.edu\/mission\/personal-cancer-risk-guides-researchers-focus\/","og_locale":"en_US","og_type":"article","og_title":"Personal cancer risk guides researcher\u2019s focus - Mission Magazine","og_description":"GLP-1 receptor agonists have revolutionized metabolic healthcare, offering effective treatment for Type 2 diabetes and obesity. As their use has expanded across the country, early studies by UT Health San Antonio researchers are beginning to show the potential anticancer effects of these therapies.","og_url":"https:\/\/magazines.uthscsa.edu\/mission\/personal-cancer-risk-guides-researchers-focus\/","og_site_name":"Mission Magazine","article_published_time":"2026-03-04T08:00:28+00:00","article_modified_time":"2026-03-10T10:34:18+00:00","og_image":[{"width":2508,"height":1173,"url":"https:\/\/magazines.uthscsa.edu\/mission\/wp-content\/uploads\/sites\/20\/2026\/03\/ColtonJones_CAedit_v5-1.jpg","type":"image\/jpeg"}],"author":"Claire Kowalick","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Claire Kowalick","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/magazines.uthscsa.edu\/mission\/personal-cancer-risk-guides-researchers-focus\/#article","isPartOf":{"@id":"https:\/\/magazines.uthscsa.edu\/mission\/personal-cancer-risk-guides-researchers-focus\/"},"author":{"name":"Claire Kowalick","@id":"https:\/\/magazines.uthscsa.edu\/mission\/#\/schema\/person\/2b00e59a35965b999b3404a426707181"},"headline":"Personal cancer risk guides researcher\u2019s focus","datePublished":"2026-03-04T08:00:28+00:00","dateModified":"2026-03-10T10:34:18+00:00","mainEntityOfPage":{"@id":"https:\/\/magazines.uthscsa.edu\/mission\/personal-cancer-risk-guides-researchers-focus\/"},"wordCount":1031,"publisher":{"@id":"https:\/\/magazines.uthscsa.edu\/mission\/#organization"},"image":{"@id":"https:\/\/magazines.uthscsa.edu\/mission\/personal-cancer-risk-guides-researchers-focus\/#primaryimage"},"thumbnailUrl":"https:\/\/magazines.uthscsa.edu\/mission\/wp-content\/uploads\/sites\/20\/2026\/03\/ColtonJones_CAedit_v5-1.jpg","articleSection":["Current"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/magazines.uthscsa.edu\/mission\/personal-cancer-risk-guides-researchers-focus\/","url":"https:\/\/magazines.uthscsa.edu\/mission\/personal-cancer-risk-guides-researchers-focus\/","name":"Personal cancer risk guides researcher\u2019s focus - Mission Magazine","isPartOf":{"@id":"https:\/\/magazines.uthscsa.edu\/mission\/#website"},"primaryImageOfPage":{"@id":"https:\/\/magazines.uthscsa.edu\/mission\/personal-cancer-risk-guides-researchers-focus\/#primaryimage"},"image":{"@id":"https:\/\/magazines.uthscsa.edu\/mission\/personal-cancer-risk-guides-researchers-focus\/#primaryimage"},"thumbnailUrl":"https:\/\/magazines.uthscsa.edu\/mission\/wp-content\/uploads\/sites\/20\/2026\/03\/ColtonJones_CAedit_v5-1.jpg","datePublished":"2026-03-04T08:00:28+00:00","dateModified":"2026-03-10T10:34:18+00:00","description":"GLP-1 receptor agonists have revolutionized metabolic healthcare, offering effective treatment for Type 2 diabetes and obesity. As their use has expanded across the country, early studies by UT Health San Antonio researchers are beginning to show the potential anticancer effects of these therapies.","breadcrumb":{"@id":"https:\/\/magazines.uthscsa.edu\/mission\/personal-cancer-risk-guides-researchers-focus\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/magazines.uthscsa.edu\/mission\/personal-cancer-risk-guides-researchers-focus\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/magazines.uthscsa.edu\/mission\/personal-cancer-risk-guides-researchers-focus\/#primaryimage","url":"https:\/\/magazines.uthscsa.edu\/mission\/wp-content\/uploads\/sites\/20\/2026\/03\/ColtonJones_CAedit_v5-1.jpg","contentUrl":"https:\/\/magazines.uthscsa.edu\/mission\/wp-content\/uploads\/sites\/20\/2026\/03\/ColtonJones_CAedit_v5-1.jpg","width":2508,"height":1173},{"@type":"BreadcrumbList","@id":"https:\/\/magazines.uthscsa.edu\/mission\/personal-cancer-risk-guides-researchers-focus\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/magazines.uthscsa.edu\/mission\/"},{"@type":"ListItem","position":2,"name":"Personal cancer risk guides researcher\u2019s focus"}]},{"@type":"WebSite","@id":"https:\/\/magazines.uthscsa.edu\/mission\/#website","url":"https:\/\/magazines.uthscsa.edu\/mission\/","name":"Mission Magazine","description":"The University of Texas Health Science Center at San Antonio Mission magazine","publisher":{"@id":"https:\/\/magazines.uthscsa.edu\/mission\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/magazines.uthscsa.edu\/mission\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/magazines.uthscsa.edu\/mission\/#organization","name":"Mission Magazine","url":"https:\/\/magazines.uthscsa.edu\/mission\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/magazines.uthscsa.edu\/mission\/#\/schema\/logo\/image\/","url":"https:\/\/magazines.uthscsa.edu\/mission\/wp-content\/uploads\/sites\/20\/2024\/10\/UTHSA_logo_H_CMYK-350.jpg","contentUrl":"https:\/\/magazines.uthscsa.edu\/mission\/wp-content\/uploads\/sites\/20\/2024\/10\/UTHSA_logo_H_CMYK-350.jpg","width":350,"height":121,"caption":"Mission Magazine"},"image":{"@id":"https:\/\/magazines.uthscsa.edu\/mission\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/magazines.uthscsa.edu\/mission\/#\/schema\/person\/2b00e59a35965b999b3404a426707181","name":"Claire Kowalick","url":"https:\/\/magazines.uthscsa.edu\/mission\/author\/claire-kowalick\/"}]}},"authors":[{"term_id":301,"user_id":684,"is_guest":0,"slug":"claire-kowalick","display_name":"Claire Kowalick","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/e31c23e218dcc4a544b3fdd9ded9e0691090c56bdb2f65e7f4cf111bfa08d5dc?s=96&d=mm&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/magazines.uthscsa.edu\/mission\/wp-json\/wp\/v2\/posts\/12505","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/magazines.uthscsa.edu\/mission\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/magazines.uthscsa.edu\/mission\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/mission\/wp-json\/wp\/v2\/users\/684"}],"replies":[{"embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/mission\/wp-json\/wp\/v2\/comments?post=12505"}],"version-history":[{"count":0,"href":"https:\/\/magazines.uthscsa.edu\/mission\/wp-json\/wp\/v2\/posts\/12505\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/mission\/wp-json\/wp\/v2\/media\/12523"}],"wp:attachment":[{"href":"https:\/\/magazines.uthscsa.edu\/mission\/wp-json\/wp\/v2\/media?parent=12505"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/mission\/wp-json\/wp\/v2\/categories?post=12505"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/mission\/wp-json\/wp\/v2\/tags?post=12505"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/mission\/wp-json\/wp\/v2\/ppma_author?post=12505"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}